EGFR and non-small cell lung carcinoma: With the exception of erlotinib, TKIs targeting EGFR have only been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with NSCLC, whose tumors frequently have activating EGFR mutations; several generations of these are available for clinical use (30) (Table 1).